echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Bristol-Myers Squibb's CAR-T therapy for second-line treatment of large B-cell lymphoma gets priority review

    Bristol-Myers Squibb's CAR-T therapy for second-line treatment of large B-cell lymphoma gets priority review

    • Last Update: 2022-05-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On February 17, 2022, Bristol-Myers Squibb (BMS) announced that the U.


    Breyanzi is an autologous CAR-T cell therapy targeting the CD19 antigen with a well-defined composition and 4-1BB co-stimulatory domain


    This application is based on positive results from a pivotal Phase 3 clinical trial


    Trial results showed that patients in the Breyanzi group achieved highly statistically and clinically meaningful improvements in event-free survival (EFS), complete response rate (CRR), and progression-free survival (PFS) compared to the standard-of-care group , and overall survival (OS) showed a positive trend


    References:

    [1] US Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb's Supplemental Biologics License Application for Breyanzi (lisocabtagene maraleucel) as a Second-Line Therapy for Relapsed or Refractory Large B-cell Lymphoma.


    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.